NDAORALTABLETPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
JAYPIRCA (pirtobrutinib) by Eli Lilly and Company is bruton's tyrosine kinase inhibitors [moa]. Approved for chronic lymphocytic leukemia, small lymphocytic lymphoma. First approved in 2023.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JAYPIRCA (pirtobrutinib) is an oral Bruton's Tyrosine Kinase (BTK) inhibitor developed by Eli Lilly and approved by the FDA on January 27, 2023. As a kinase inhibitor, it works by blocking BTK signaling in B-cell malignancies. The product is currently in its peak lifecycle stage, indicating it has achieved market approval and is in active commercial distribution.
$0.0BPart D
15.4 years to LOEMechanism of Action
Bruton's Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Worked on JAYPIRCA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.